Marina Simian

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8172225/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Organoids: A historical perspective of thinking in three dimensions. Journal of Cell Biology, 2017, 216, 31-40.	5.2	442
2	The interplay of matrix metalloproteinases, morphogens and growth factors is necessary for branching of mammary epithelial cells. Development (Cambridge), 2001, 128, 3117-3131.	2.5	317
3	The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin. Breast Cancer Research and Treatment, 2012, 133, 459-471.	2.5	143
4	Epimorphin Mediates Mammary Luminal Morphogenesis through Control of C/EBPβ. Journal of Cell Biology, 2001, 153, 785-794.	5.2	67
5	Decreased metastatic phenotype in cells resistant to aminolevulinic acid-photodynamic therapy. Cancer Letters, 2008, 271, 342-351.	7.2	32
6	Tamoxifen selects for breast cancer cells with mammosphere forming capacity and increased growth rate. Breast Cancer Research and Treatment, 2013, 142, 537-548.	2.5	32
7	Regulation of cell growth of a progestin-dependent murine mammary carcinoma in vitro: progesterone receptor involvement in serum or growth factor-induced cell proliferation. Journal of Steroid Biochemistry and Molecular Biology, 1999, 70, 133-142.	2.5	31
8	AhR ligand Aminoflavone inhibits α6-integrin expression and breast cancer sphere-initiating capacity. Cancer Letters, 2016, 376, 53-61.	7.2	30
9	Fibronectin rescues estrogen receptor α from lysosomal degradation in breast cancer cells. Journal of Cell Biology, 2018, 217, 2777-2798.	5.2	30
10	The Tumor Microenvironment as a Regulator of Endocrine Resistance in Breast Cancer. Frontiers in Endocrinology, 2019, 10, 547.	3.5	26
11	Angiotensin-(1-7) counteracts the transforming effects triggered by angiotensin II in breast cancer cells. Oncotarget, 2017, 8, 88475-88487.	1.8	26
12	Involvement of Matrix Metalloproteinase Activity in Hormone-Induced Mammary Tumor Regression. American Journal of Pathology, 2006, 168, 270-279.	3.8	22
13	Establishment of an inÂvitro estrogen-dependent mouse mammary tumor model: a new tool to understand estrogen responsiveness and development of tamoxifen resistance in the context of stromal–epithelial interactions. Breast Cancer Research and Treatment, 2009, 116, 247-255.	2.5	22
14	iRGD-guided tamoxifen polymersomes inhibit estrogen receptor transcriptional activity and decrease the number of breast cancer cells with self-renewing capacity. Journal of Nanobiotechnology, 2019, 17, 120.	9.1	19
15	Involvement of insulin-like growth factors-I and -II and their receptors in medroxyprogesterone acetate-induced growth of mouse mammary adenocarcinomas. Journal of Steroid Biochemistry and Molecular Biology, 1998, 67, 305-317.	2.5	18
16	A spontaneous estrogen dependent, tamoxifen sensitive mouse mammary tumor: a new model system to study hormone-responsiveness in immune competent mice. Breast Cancer Research and Treatment, 2009, 113, 1-8.	2.5	18
17	Estrategias para Mejorar la Comprensión Lectora: Impacto de un Programa de Intervención en Español. Psicologia Educativa, 2019, 25, 91-99.	0.9	16
18	Laminin Modulates the Stem Cell Population in LM05-E Murine Breast Cancer Cells through the Activation of the MAPK/ERK Pathway. Cancer Research and Treatment, 2017, 49, 869-879.	3.0	15

MARINA SIMIAN

#	Article	IF	CITATIONS
19	Estrogen and progesterone receptors have distinct roles in the establishment of the hyperplastic phenotype in PR-A transgenic mice. Breast Cancer Research, 2009, 11, R72.	5.0	14
20	Role of MMPs in Metastatic Dissemination: Implications for Therapeutic Advances. Current Pharmaceutical Biotechnology, 2011, 12, 1937-1947.	1.6	14
21	The Hyperplastic Phenotype in PR-A and PR-B Transgenic Mice. Vitamins and Hormones, 2013, 93, 185-201.	1.7	12
22	Involvement of EGF in medroxyprogesterone acetate (MPA)-induced mammary gland hyperplasia and its role in MPA-induced mammary tumors in BALB/c mice. Cancer Letters, 1998, 126, 49-57.	7.2	11
23	2-C-Methyluridine modified hammerhead ribozyme against the estrogen receptor. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2806-2808.	2.2	10
24	The combination of bleomycin with suicide or interferon-β gene transfer is able to efficiently eliminate human melanoma tumor initiating cells. Biomedicine and Pharmacotherapy, 2016, 83, 290-301.	5.6	10
25	Distinct ErbB2 receptor populations differentially interact with beta1 integrin in breast cancer cell models. PLoS ONE, 2017, 12, e0174230.	2.5	9
26	AT ₁ receptor blockade delays postlactational mammary gland involution: a novel role for the renin angiotensin system. FASEB Journal, 2012, 26, 1982-1994.	0.5	8
27	Microenvironment and endocrine resistance in breast cancer: Friend or foe?. World Journal of Clinical Oncology, 2015, 6, 207.	2.3	8
28	In vitro studies of cellular response to DNA damage induced by boron neutron capture therapy. Applied Radiation and Isotopes, 2011, 69, 1732-1736.	1.5	7
29	Isolation of a stromal cell line from an early passage of a mouse mammary tumor line: A model for stromal parenchymal interactions. Journal of Cellular Physiology, 2005, 202, 672-682.	4.1	6
30	Reversal of the Migratory and Invasive Phenotype of Ras-Transfected Mammary Cells by Photodynamic Therapy Treatment. Journal of Cellular Biochemistry, 2017, 118, 464-477.	2.6	6
31	Gene expression profile and cancer-associated pathways linked to progesterone receptor isoform a (PRA) predominance in transgenic mouse mammary glands. BMC Cancer, 2018, 18, 682.	2.6	6
32	Non-genomic actions of estradiol and 4-OH-tamoxifen on murine breast cancer cells. Oncology Reports, 2015, 33, 439-447.	2.6	5
33	Alterations in Progesterone Receptor Isoform Balance in Normal and Neoplastic Breast Cells Modulates the Stem Cell Population. Cells, 2020, 9, 2074.	4.1	5
34	A Heterotypic Tridimensional Model to Study the Interaction of Macrophages and Glioblastoma In Vitro. International Journal of Molecular Sciences, 2021, 22, 5105.	4.1	4
35	Human-specific approaches to brain research for the 21st century: a South American perspective. Drug Discovery Today, 2018, 23, 1929-1935.	6.4	1
36	Valor predictor y discriminante de la velocidad de nombrado en español: experiencia con niños argentinos Ocnos, 2019, 18, 85-96.	0.5	1